Home
CADL
CADL News

Latest Candel Therapeutics Inc. (CADL) News on June 4, 2025

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

Zacks

2 days ago

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer

Insider Monkey

5 days ago

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Zacks

6 days ago

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

MT Newswires

7 days ago

Candel Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Prostate Cancer Drug

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

GlobeNewswire

7 days ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

GlobeNewswire

8 days ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025

Insider Monkey

12 days ago

Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

GlobeNewswire

12 days ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Best Momentum Stocks to Buy for May 19th

Zacks

16 days ago

Best Momentum Stocks to Buy for May 19th

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

GlobeNewswire

22 days ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a month ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

GlobeNewswire

a month ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

GlobeNewswire

2 months ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients

Benzinga

2 months ago

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients

MT Newswires

2 months ago

Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

GlobeNewswire

2 months ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now

Zacks

2 months ago

Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now

MT Newswires

2 months ago

Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

GlobeNewswire

2 months ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

GlobeNewswire

3 months ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire

3 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.

3 months ago

Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them.

Candel Therapeutics stock drops despite OS improvement in PDAC trial

Clinical Trials Arena

3 months ago

Candel Therapeutics stock drops despite OS improvement in PDAC trial

MT Newswires

3 months ago

Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

GlobeNewswire

3 months ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

MT Newswires

3 months ago

Citigroup Initiates Candel Therapeutics at Buy With $25 Price Target

Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment

Simply Wall St.

5 months ago

Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

GlobeNewswire

5 months ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win

Pharma Voice

5 months ago

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win

MT Newswires

6 months ago

Candel Therapeutics Closes Securities Offering to Raise $92 Million

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire

6 months ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

MT Newswires

6 months ago

Update: Candel Therapeutics Prices $80 Million Public Offering -- Shares Fall

MT Newswires

6 months ago

Top Midday Decliners

MT Newswires

6 months ago

Sector Update: Health Care Stocks Steady Premarket Friday

MT Newswires

6 months ago

Candel Therapeutics Prices $80 Million Public Offering

Candel Therapeutics Announces Pricing of Public Offering

GlobeNewswire

6 months ago

Candel Therapeutics Announces Pricing of Public Offering

Candel Therapeutics Announces $80 Million Proposed Public Offering

GlobeNewswire

6 months ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

Zacks

6 months ago

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug

Investor's Business Daily

6 months ago

Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug

MT Newswires

6 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires

6 months ago

Top Midday Gainers

Candel Therapeutics Prostate Cancer Therapy Shows Promise

Exec Edge

6 months ago

Candel Therapeutics Prostate Cancer Therapy Shows Promise

Candel Therapeutics Prostate Cancer Therapy Shows Promise

Exec Edge

6 months ago

Candel Therapeutics Prostate Cancer Therapy Shows Promise

Candel Therapeutics stock up 172% after Phase III prostate cancer success

Clinical Trials Arena

6 months ago

Candel Therapeutics stock up 172% after Phase III prostate cancer success

MT Newswires

6 months ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday

Candel Therapeutics Stock Surges Over 100% - Here's Why

Benzinga

6 months ago

Candel Therapeutics Stock Surges Over 100% - Here's Why

Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug

Investor's Business Daily

6 months ago

Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug

MT Newswires

6 months ago

Candel Therapeutics Says Prostate Cancer Drug Trial Meets Primary Endpoint; Shares Jump

MT Newswires

6 months ago

Top Premarket Gainers

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

GlobeNewswire

6 months ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire

7 months ago

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

GlobeNewswire

7 months ago

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

GlobeNewswire

7 months ago

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Candel Therapeutics Advances in Cancer Treatment Trials

TipRanks

7 months ago

Candel Therapeutics Advances in Cancer Treatment Trials

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

GlobeNewswire

7 months ago

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

GlobeNewswire

8 months ago

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30%

Simply Wall St.

9 months ago

Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30%

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

GlobeNewswire

9 months ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

9 months ago

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

MT Newswires

10 months ago

Candel Therapeutics Shares Rise After Q2 Results

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire

10 months ago

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

GlobeNewswire

a year ago

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Candel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

ACCESSWIRE

a year ago

Candel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Candel Therapeutics to Join Russell 3000® Index

GlobeNewswire

a year ago

Candel Therapeutics to Join Russell 3000® Index

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

ACCESSWIRE

a year ago

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

MT Newswires

a year ago

FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

GlobeNewswire

a year ago

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

Zacks

a year ago

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

Candel (CADL) Reports Upbeat Data From Lung Cancer Study

Zacks

a year ago

Candel (CADL) Reports Upbeat Data From Lung Cancer Study

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

GlobeNewswire

a year ago

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

GlobeNewswire

a year ago

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire

a year ago

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

GlobeNewswire

a year ago

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag

Zacks

a year ago

Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

GlobeNewswire

a year ago

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

GlobeNewswire

a year ago

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded

Simply Wall St.

a year ago

Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

Zacks

a year ago

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study

Benzinga

a year ago

After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

GlobeNewswire

a year ago

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

GlobeNewswire

a year ago

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire

a year ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

GlobeNewswire

a year ago

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

GlobeNewswire

a year ago

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

GlobeNewswire

a year ago

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

Associated Press Finance

a year ago

IF Bancorp: Fiscal Q2 Earnings Snapshot

Business Wire

a year ago

IF Bancorp, Inc. Announces Results for Second Quarter of Fiscal Year 2024

Business Wire

a year ago

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office

CFSB BANCORP, INC. ANNOUNCES FISCAL SECOND QUARTER AND YEAR-TO-DATE 2024 FINANCIAL RESULTS

PR Newswire

a year ago

CFSB BANCORP, INC. ANNOUNCES FISCAL SECOND QUARTER AND YEAR-TO-DATE 2024 FINANCIAL RESULTS

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

Business Wire

a year ago

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

GuruFocus.com

a year ago

FVCBankcorp Inc (FVCB) Reports Mixed Results Amidst Strategic Repositioning

Share on Social Networks: